Nicole Onetto
Pharmaceuticals
Basilea Pharmaceutica Ltd
Switzerland
Biography
Dr. Nicole Onetto, a French and Canadian citizen, was elected as a member of the Board of Directors in April 2017. She is currently an independent consultant in oncology, drug development and translational research. Previously, from 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada. From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc. Between 2002 and 2005, she served at OSI Pharmaceuticals, Inc., first as Executive Vice President-Oncology, and then as Chief Medical Officer and Executive Vice President. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc. She is currently on the board of ProNAi Therapeutics, a Vancouver-based oncology hematology company, and on the board of NBE Therapeutics AG, a Basel-based biotechnology company, and previously served for eleven years as a member of the board of ImmunoGen Inc. Dr. Onetto obtained her MD from the University of Paris and holds a Master of Pharmacology from the University of Montréal. Dr. Nicole Onetto, a French and Canadian citizen, was elected as a member of the Board of Directors in April 2017. She is currently an independent consultant in oncology, drug development and translational research. Previously, from 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada. From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc. Between 2002 and 2005, she served at OSI Pharmaceuticals, Inc., first as Executive Vice President-Oncology, and then as Chief Medical Officer and Executive Vice President. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc. She is currently on the board of ProNAi Therapeutics, a Vancouver-based oncology hematology company, and on the board of NBE Therapeutics AG, a Basel-based biotechnology company, and previously served for eleven years as a member of the board of ImmunoGen Inc. Dr. Onetto obtained her MD from the University of Paris and holds a Master of Pharmacology from the University of Montréal.
Research Interest
Pharmaceutical Sciences, biotechnology,
